|
The Immunohistochemistry Antibody Company
|
|
|
General Cancer Screen 27 Tissue Microarray - LS-SCA27This tissue microarray is available for use in LSBio Immunohistochemistry Studies only. |
| Catalog ID: | LS-SCA27 |
| Product Name: | General Cancer Screen 27 |
| Description: | 15 major cancer types |
| Format: | FFPE |
| Category: | Human Multi-Tumor |
| QA/QC: | H&E reviewed; IHC validated with a positive control antibody |
| Storage: | Short term RT; Long term 4ºC |
| Clinical History: | No |
| Tissue Marker: | No |
| Stage/Grade: | Yes |
| Core Diameter: | 2 mm |
| Core Thickness: | 4 µm |
| Cases: | 20 |
| Cores: | 39 |
| Slides Per Set: | 1 |
LS-SCA27 Tissue Microarray Map
Slide Number 1
| LABEL |
|
Diagnosis Type Legend
| Benign non-neoplastic | Diseased | Inflammatory | Malignant | Metastatic | Tumor | Unknown |
Element Tissue Legend
Bladder (Bla); Breast (Bst); Colon (Col); Kidney (Kid); Kidney, Cortex (Kid); Liver (Liv); Lung (Lng); Lymph node (Lym); Ovary (Ova); Pancreas (Pnc); Prostate (Pst); Skin (Skn); Skin, Back (Skn); Stomach (Sto); Uterus (Ute); Uterus, Endometrium (Ute);
LS-SCA27 Element Details
| Slide | Position | Species | Gender | Age | Tissue | Diagnosis | Diagnosis Type | TNM Tumor Classification | Tumor Grade |
|---|---|---|---|---|---|---|---|---|---|
| 1 | A1 | Human | M | 45 y | Bladder (Bla) | Normal | Benign non-neoplastic | ||
| 1 | A2 | Human | M | 80 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T2N0M0 | Grade I-II |
| 1 | A3 | Human | M | 51 y | Bladder (Bla) | Transitional cell carcinoma | Malignant | T1N0M0 | Grade II |
| 1 | A4 | Human | F | 38 y | Breast (Bst) | Normal | Benign non-neoplastic | ||
| 1 | A5 | Human | F | 37 y | Breast (Bst) | Tubular mixed carcinoma, Invasive | Malignant | T1N1M0 | |
| 1 | A6 | Human | F | 43 y | Breast (Bst) | Ductal carcinoma, infiltrating | Malignant | T2N1M0 | |
| 1 | A7 | Human | M | 71 y | Stomach (Sto) | Normal | Benign non-neoplastic | ||
| 1 | A8 | Human | F | 69 y | Stomach (Sto) | Adenocarcinoma | Malignant | T2N1M0 | Grade I-II |
| 1 | B1 | Human | M | 65 y | Stomach (Sto) | Adenocarcinoma | Malignant | T3N1M0 | Grade II-III |
| 1 | B2 | Human | F | 10 mo | Colon (Col) | Normal | Benign non-neoplastic | ||
| 1 | B3 | Human | F | 60 y | Colon (Col) | Carcinoma | Malignant | T2N1M1 | Grade II |
| 1 | B4 | Human | F | 85 y | Colon (Col) | Carcinoma | Malignant | T2N0M0 | Grade II-III |
| 1 | B5 | Human | F | 2 y | Kidney, Cortex (Kid) | Normal | Benign non-neoplastic | ||
| 1 | B6 | Human | F | 53 y | Kidney (Kid) | Clear cell carcinoma | Malignant | T1N0M0 | Grade II |
| 1 | B7 | Human | M | 44 y | Kidney (Kid) | Clear cell carcinoma | Malignant | T1N0M0 | Grade III |
| 1 | B8 | Human | M | 52 y | Liver (Liv) | Normal | Benign non-neoplastic | ||
| 1 | C1 | Human | M | 33 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | Grade II |
| 1 | C2 | Human | M | 47 y | Liver (Liv) | Hepatocellular carcinoma | Malignant | T2N0M0 | Grade I-II |
| 1 | C3 | Human | M | 60 y | Lung (Lng) | Normal | Benign non-neoplastic | ||
| 1 | C4 | Human | M | 69 y | Lung (Lng) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II-III |
| 1 | C5 | Human | M | 70 y | Lung (Lng) | Adenocarcinoma | Malignant | T2N1M0 | Grade II |
| 1 | C6 | Human | F | 39 y | Lymph node (Lym) | Reactive | Inflammatory | ||
| 1 | C7 | Human | M | 40 y | Lymph node (Lym) | Hodgkin's lymphoma | Malignant | ||
| 1 | C8 | Human | F | 77 y | Lymph node (Lym) | Non-Hodgkin's B cell lymphoma | Malignant | ||
| 1 | D1 | Human | F | 16 y | Ovary (Ova) | Normal | Benign non-neoplastic | ||
| 1 | D2 | Human | F | 20 y | Ovary (Ova) | Adenocarcinoma | Malignant | T2N0M0 | Grade I-II |
| 1 | D3 | Human | F | 45 y | Ovary (Ova) | Adenocarcinoma | Malignant | T2aN0M0 | Grade III |
| 1 | D4 | Human | M | 46 y | Pancreas (Pnc) | Normal | Benign non-neoplastic | ||
| 1 | D5 | Human | F | 64 y | Pancreas (Pnc) | Adenocarcinoma | Malignant | T1N0M0 | Grade I-II |
| 1 | D6 | Human | F | 49 y | Pancreas (Pnc) | Adenocarcinoma | Malignant | T1N0M0 | Grade II-III |
| 1 | D7 | Human | M | 74 y | Prostate (Pst) | Normal | Benign non-neoplastic | ||
| 1 | D8 | Human | M | 54 y | Prostate (Pst) | Transitional cell carcinoma | Malignant | T1N0M0 | Grade II |
| 1 | E1 | Human | M | 60 y | Prostate (Pst) | Adenocarcinoma | Malignant | T1N0M0 | Grade II |
| 1 | E2 | Human | F | 48 y | Skin (Skn) | Normal | Benign non-neoplastic | ||
| 1 | E3 | Human | M | 67 y | Skin, Back (Skn) | Squamous cell carcinoma | Malignant | T2N0M0 | Grade II |
| 1 | E4 | Human | M | 49 y | Skin (Skn) | Melanoma | Tumor | T2N0M0 | Grade II |
| 1 | E5 | Human | F | 47 y | Uterus (Ute) | Normal | Benign non-neoplastic | ||
| 1 | E6 | Human | F | 43 y | Uterus (Ute) | Squamous cell carcinoma | Malignant | T1N0M0 | Grade II |
| 1 | E7 | Human | F | 44 y | Uterus, Endometrium (Ute) | Endometrial adenocarcinoma | Malignant | T1bN0M0 | Grade II |